Tunlametinib

Tunlametinib is a highly selective, orally active MEK1/2 inhibitor (IC50=1.9 nM, MEK1). Tunlametinib blocks the RAS-RAF-MEK-ERK signaling pathway, arrests tumor cell cycle and promotes apoptosis. Tunlametinib potently inhibits the proliferation of RAS/RAF mutant cancer cells (such as BRAF V600E, KRAS G12C mutant cells). Tunlametinib shows synergistic anti-tumor effects with BRAF/KRAS G12C/SHP2 inhibitors, Docetaxel. Tunlametinib can be used to study targeted therapy for RAS/RAF mutation-driven malignancies (such as melanoma, colorectal cancer, and non-small cell lung cancer) .


Cat. No.: EX-A10458	Purity: >98%

	Chemical structure of Tunlametinib

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
100mg	600	In-stock
250mg	850	In-stock
500mg	1185	In-stock
1g	1985	In-stock
2g	3300	In-stock
5g	get quote	In-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


Synonyms	HL-085
CAS No.	1801756-06-8
Purity	>98%
Formula	C16H12F2IN3O3S
Mol Weight	491.251
Color	off-white to light yellow
State	solid
Solubility	soluble in DMSO
Shelf Life	>3 years if stored properly
Storage	Powder 4℃ 2 year; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Liu Y, et al. Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor. Front Pharmacol. 2023 Sep 21;14:1271268. [2]. Sari MHM, et al. Editorial: Advances in molecular and pharmacological mechanisms of novel targeted therapies for melanoma. Front Oncol. 2024 Apr 4;14:1403778.
CoA	CoA of Tunlametinib

Smiles:	O=C(C1=CC2=C(C(F)=C1NC3=CC=C(C=C3F)I)N=CS2)NOCCO


		Search